Molecular Characterization and Therapeutic Implications of MYD88 and CDKN2A in Primary CNS Lymphoma
Anticancer Research · 2025
DOI: 10.21873/anticanres.17705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Ryouta Taomoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Fukuoka University of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, Central Nervous System Neoplasms, Cyclin-Dependent Kinase Inhibitor p16, Lymphoma, Large B-Cell, Diffuse.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Fukuoka University of Medicine, Fukuoka, Japan.
- Department of Pathology, Fukuoka University of Medicine, Fukuoka, Japan.
- Department of Pathology, Fukuoka University of Medicine, Fukuoka, Japan; mikikoss@fukuoka-u.ac.jp.
- Department of Neurosurgery, Hakujuji Hospital, Fukuoka, Japan.
- Department of Pathology, Fukuoka Tokushukai Hospital, Fukuoka, Japan.
Zitieren
APA
Taomoto, R., Aoki, M., Enomoto, T., Inoue, T., Nabeshima, K., Hamasaki, M., & Abe, H. (2025). Molecular Characterization and Therapeutic Implications of MYD88 and CDKN2A in Primary CNS Lymphoma. Anticancer Research. https://doi.org/10.21873/anticanres.17705
Vancouver
Taomoto R, Aoki M, Enomoto T, Inoue T, Nabeshima K, Hamasaki M, et al. Molecular Characterization and Therapeutic Implications of MYD88 and CDKN2A in Primary CNS Lymphoma. Anticancer Research. 2025. doi:10.21873/anticanres.17705
BibTeX
@article{Taomoto2025,
author = {Taomoto, Ryouta and Aoki, Mikiko and Enomoto, Toshiyuki and Inoue, Tooru and Nabeshima, Kazuki and Hamasaki, Makoto and Abe, Hiroshi},
title = {Molecular Characterization and Therapeutic Implications of MYD88 and CDKN2A in Primary CNS Lymphoma},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17705}
}
EUVIMED